Brian Klein

Brian Klein, Ph.D.

Scientific Project Manager
Photo of Brian Klein
Areas of Interest:
Epilepsy Therapy Screening Program (ETSP), Preclinical Pharmacology, Animal Models. Preclinical Neurotherapeutic Development

Dr. Klein joined the National Institute of Neurological Disorders and Stroke (NINDS) in May 2015 in the Office of Translational Research and currently serves as a Scientific Project Manager for the Epilepsy Therapy Screening Program (ETSP).

Dr. Klein received his Ph.D. in Pharmacology and Toxicology from the University of Utah, with dissertation work characterizing a genetic model of epilepsy. He then joined Cognetix a biotech company identifying novel venom-based peptides acting on neuronal and ion channel targets for treating neurological disorders. Thereafter, Dr. Klein joined Johnson & Johnson Pharmaceutical R&D as a Drug Discovery Scientist in CNS Research and Early Development where his activities included serving as a preclinical pharmacologist on compound development teams for antiseizure drugs in multiple indications. Subsequently, Dr. Klein was the Director of Pharmacology at Neuroadjuvants, Inc. and responsible for the preclinical development of neuropeptides for epilepsy and other disorders. Prior to joining NINDS Dr. Klein served as a Program Director at the National Cancer Institute (NCI) Chemopreventive Agent Development Research Group where he was responsible for drug evaluation of agents approved for the NCI PREVENT Cancer Drug Development Program.